Click to show/hide details.
The presentation can be found here.
The talk was well received with active discussion afterward regarding several subjects. These included the use of cells in combination with in-house tissue as part of the NEQAS submissions for the scheme and how top marks are achievable using them in combination, whereas cells alone (properly working) will only give you 3/5. NEQAS need to see the quality of the tissue produced by the participating laboratory and how it performs immunohistochemically. There were further questions around cells for use in cytology, something HistoCyte are aware of as a utility but as yet do not know the needs of the wider market.
The meeting itself saw many companies presenting on their new products and initiatives as well as describing the journey they took on their way to success. We understand how difficult this journey can be so are delighted to receive recognition for our efforts. Initially shortlisted as one of five, HistoCyte went on to win the category for Innovation in Healthcare due to our development of novel cell line based controls in research and diagnostics and the subsequent commercialisation that has seen us generate interest around the world.
Self-funded, HistoCyte has relied on the ability of the team in-house to develop and perfect the technology. Having spent 20-30 years in this market, we had the right contacts and network to facilitate the commercial phase. Knowing the market and having excellent relationships with our customers, combined with the technical aptitude we have developed in-house, has meant we have produced product of high quality that meets the customer’s needs on every level.
Colin Tristram received the award on behalf of the team at the meeting held in St James’ Park, Newcastle upon Tyne.
The low/intermediate (cell line B) and intermediate/high (cell line C) provide a suitable array of cells with varying expression that easily demonstrate whether the assay is running at a suitable sensitivity in your laboratory. Reproducible, robust and cost effective, these are another great addition to the quality control of IHC.
For more information, please contact info@histocyte.
For more information, please contact info@histocyte.
For any enquiries, please contact info@histocyte.
In clinical trials the volume of control material for same slide use is excessive and therefore not consistent across all the tests considering the number of samples assessed. An inexhaustible supply of standardised material was extremely beneficial in this case. For external quality assurance assessments, while interpretation on tissue is important, standardised material to determine the technical aspects is vital. Of course the material lends itself to routine use being a cost-effective control for same slide use as previously described.
In this summary we provide some background to the product, the diseases and how the use of our control material can improve confidence in HPV in situ hybridisation and p16 immunohistochemistry results. It also details the results and findings of a ring study where we demonstrate the effectiveness across a number of sites. If you would like more information, please contact info@histocyte.
Arunn Sri Ravichelvan looked at what “failed” immunohistochemistry (IHC) tests with the cells looked like by image analysis. He did this by creating a baseline reading from standard IHC runs. He was then able to compare the following to this baseline: section thickness, inappropriate epitope retrieval, incubation times and antibody concentration. A pdf of the poster can be found here.
With additional data from other groups we will look to include this data in a future publication. This current data demonstrated how stable the product is across three independent batches of product. In addition to being a good quality control tool it could potentially help in troubleshooting a failed test.
We wish Arunn all the best for his future studies.
This product is expected to be launched in early 2018. For any enquiries, please contact info@histocyte.
A copy of our certificate can be found here.
Dr Robinson has written a chapter in HPV Infection in Head and Neck Cancer, Recent Results in Cancer Research, Volume 206, Springer 2106, pages 101 to 111, in which he provides a review of current testing of HPV in head and neck cancer in clinical practice. As part of his review he discusses the need for standardised controls and refers to the HistoCyte Laboratories Ltd products as one means to meet these requirements.
It has been a pleasure working with Dr Robinson on this project and we look forward to future projects.
In either case the analyte controls demonstrate that the reagents employed to perform the assay have worked effectively in combination with the staining protocol. Please visit our products page for more information.
UKNEQAS (the United Kingdom National External Quality Assurance Scheme for ICC and ISH) assessments have often noted that internal control tissue being used routinely in subscribing laboratories is inappropriate or incomplete. The lack of availability of suitable control tissue means a laboratory may only have some of the tissue required to demonstrate the necessary expression levels of a given biomarker optimally. This finding highlights an increasing need for standardised control material for IHC and ISH testing, which in turn introduces the challenge of providing a cost effective solution that can be applied to every case tested.
I am very excited by what HistoCyte Laboratories Ltd will bring to this field and look forward to collaborating with Ian Milton and Colin Tristram as I have done in their previous enterprises. UKNEQAS works closely with industry partners in order to deliver high quality solutions to our colleagues in laboratories throughout the UK and beyond. Only through collaborating with the industry can we ensure that our needs are met and ultimately make sure quality services are delivered to the patient.
2Bogen SA, Vani K, McGraw B, Federico V, Habib I, Zeheb R, Luther E, Tristram C, Sompuram SR. Experimental validation of peptide immunohistochemistry controls. Appl Immunohistochem Mol Morphol. 2009 May;17(3):239-46.